Intravenous Direct Thrombin Inhibitors for Acute Venous Thromboembolism or Heparin-Induced Thrombocytopenia with Thrombosis in Children: A Systematic Review of the Literature
Systematic review published in Seminars in Thrombosis and Hemostasis (2024)
Abstract
Intravenous direct thrombin inhibitors (DTIs) are used for thromboembolic disorders. This systematic review aims to characterize intravenous DTI agents, dosing, monitoring strategies (or use), bleeding, and mortality, in pediatric patients with acute venous thromboembolism (VTE) or heparin-induced thrombocytopenia with thrombosis (HITT). MEDLINE, Embase, and Cochrane's CENTRAL were searched from inception through July 2023. Case series, retrospective studies, and prospective studies providing per-patient or summary data for patients < 18 years of age with VTE or HITT treated with an intravenous DTI were included. Selection and data extraction were conducted independently by two reviewers. Sixteen studies (7 case reports, 1 case series, 5 retrospective studies, 3 prospective studies) with 85 patients were included. Target conditions included acute VTE in 54 (64%) and HITT in 31 (36%) patients. Bivalirudin, argatroban, and lepirudin were used in 52 (61%), 27 (32%), and 6 (7%) patients, respectively. Fifty-two (61%) patients received a bolus dose, and weighted mean infusion rates for bivalirudin, argatroban, and lepirudin were 0.2 mg/kg/hr, 1.2 mcg/kg/min, and 0.15 mg/kg/hr, respectively. The activated partial thromboplastin time was utilized for monitoring in 82 (96%) patients. Complete or partial thrombus resolution was reported in 53 (62%) patients, mortality in 6 (7%) patients, and bleeding complications in 14 (16%) patients. In this systematic review involving 85 pediatric patients treated with an intravenous DTI for acute VTE or HITT, bivalirudin was the most commonly utilized agent, with a rate of resolution over 60% despite a high acuity in the population studied. Prospective collaborative studies are warranted to establish optimal dosing and further characterize VTE and bleeding outcomes.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Systematic review of 16 studies and 85 pediatric patients receiving bivalirudin (61%), argatroban (32%) or lepirudin (7%) for acute VTE or HIT with thrombosis; 62% achieved thrombus resolution with 16% bleeding complication rate.
Why This Matters for Hirudotherapy
This systematic review characterized intravenous direct thrombin inhibitor use in 85 pediatric patients with acute venous thromboembolism or heparin-induced thrombocytopenia with thrombosis, drawing on case reports, case series, retrospective, and prospective studies. Lepirudin was used in 6 patients (7%), while bivalirudin (61%) and argatroban (32%) were more common; complete or partial thrombus resolution occurred in 62% overall. The abstract does not describe lepirudin's relationship to hirudin or mention leeches. The connection to hirudotherapy or the leech secretome is not supported by the abstract, which discusses these agents purely as direct thrombin inhibitors. The evidence base is observational, and prospective collaborative studies are warranted.
Citation
Reference (Vancouver style)
Kiskaddon AL, Branstetter J, Williams P, Ignjatovic V, Memken A, Wilhoit K, et al. Intravenous Direct Thrombin Inhibitors for Acute Venous Thromboembolism or Heparin-Induced Thrombocytopenia with Thrombosis in Children: A Systematic Review of the Literature. Semin Thromb Hemost. 2025;51(3):329-334. doi:10.1055/s-0044-1791534. PMID: 39374846
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026